Seminars in Diagnostic Pathology最新文献

Intraductal neoplasms of the pancreas: Current concepts and controversies regarding definitions, evolving classifications, diagnostic challenges and clinical significance. 胰腺导管内肿瘤：关于定义、分类演变、诊断挑战和临床意义的当前概念和争议。

IF 3.5 3区医学

Seminars in Diagnostic Pathology Pub Date : 2026-03-03 DOI: 10.1016/j.semdp.2026.150996

Irem Guvendir Bakkaloglu, Volkan Adsay, Olca Basturk

{"title":"Intraductal neoplasms of the pancreas: Current concepts and controversies regarding definitions, evolving classifications, diagnostic challenges and clinical significance.","authors":"Irem Guvendir Bakkaloglu, Volkan Adsay, Olca Basturk","doi":"10.1016/j.semdp.2026.150996","DOIUrl":"https://doi.org/10.1016/j.semdp.2026.150996","url":null,"abstract":"<p><p>Intraductal neoplasms of the pancreas encompass a spectrum of epithelial proliferations within the pancreatic ductal system and are broadly classified into flat-type and mass-forming lesions. Flat-type neoplasms, such as pancreatic intraepithelial neoplasia (PanIN), consist of microscopic epithelial changes, whereas mass-forming intraductal neoplasms-including intraductal papillary mucinous neoplasm (IPMN), intraductal oncocytic papillary neoplasm (IOPN), and intraductal tubulopapillary neoplasm (ITPN)-produce clinically or radiologically detectable ductal dilatation or cystic masses. Both categories represent important precursors to invasive pancreatic carcinoma, and accurate classification, grading, and distinction between pseudo-invasion and true invasion remain critical for patient management and prognostication. Gastric-type IPMNs, most often arising in branch ducts, tend to exhibit indolent behavior. Intestinal-type IPMNs, typically involving the main duct and characterized by MUC2 and CDX2 expression, carry a higher risk of progression to invasive colloid carcinoma, which generally has a more favorable outcome. Pancreatobiliary-type IPMNs frequently involve the main duct, express MUC1 and MUC5AC, and more commonly progress to tubular invasive carcinoma resembling pancreatic ductal adenocarcinoma. IOPN and ITPN constitute distinct mass-forming intraductal neoplasms. IOPN typically presents as a large cystic lesion with complex papillary architecture and demonstrates recurrent PRKACA or PRKACB fusions. ITPN is defined by its predominantly tubular growth pattern, mucin-poor phenotype, and absence of MUC5AC expression. Both entities are associated with favorable outcomes following complete resection. Recognition of these intraductal neoplasms is essential, as they must be distinguished from other cystic pancreatic lesions such as mucinous cystic neoplasm (MCN), which is defined by its characteristic ovarian-type stroma.</p>","PeriodicalId":49548,"journal":{"name":"Seminars in Diagnostic Pathology","volume":" ","pages":"150996"},"PeriodicalIF":3.5,"publicationDate":"2026-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147437012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MASTHEAD (p/u from previous issue) 报头（p/u从上一期）

IF 3.5 3区医学

Seminars in Diagnostic Pathology Pub Date : 2026-03-01 Epub Date: 2026-03-12 DOI: 10.1053/S0740-2570(26)00026-2

引用次数: 0

COVER (PMS 180&K) (p/u from previous issue w/updates) 封面（PMS 180&K）（p/u来自上一期，并有更新）

IF 3.5 3区医学

Seminars in Diagnostic Pathology Pub Date : 2026-03-01 Epub Date: 2026-03-12 DOI: 10.1053/S0740-2570(26)00025-0

引用次数: 0

Histologic mimics of urothelial carcinoma 尿路上皮癌的组织学模拟。

IF 3.5 3区医学

Seminars in Diagnostic Pathology Pub Date : 2026-03-01 Epub Date: 2026-01-29 DOI: 10.1016/j.semdp.2026.150993

Douglas Jian-Xian Wu, Emily Chan

{"title":"Histologic mimics of urothelial carcinoma","authors":"Douglas Jian-Xian Wu, Emily Chan","doi":"10.1016/j.semdp.2026.150993","DOIUrl":"10.1016/j.semdp.2026.150993","url":null,"abstract":"<div><div>Conventional urothelial carcinoma in its invasive form has a relatively nonspecific morphologic description, frequently described as nests of epithelial cells containing hyperchromatic and pleomorphic nuclei, with readily identified mitotic figures, and moderate amounts of eosinophilic cytoplasm, infiltrating as irregular nests, single cells or solid sheets. The presence of a noninvasive papillary or flat component (urothelial carcinoma in situ), combined with the clinical presentation of a urinary bladder mass, typically helps to make the diagnosis. However, morphologic mimics of urothelial carcinoma are not uncommon and they can mimic both invasive and noninvasive forms, range from benign to malignant, and therefore pose significant diagnostic pitfalls that have profound effect on a patient’s treatment planning and prognostic implications. Herein, we discuss some of the diagnostic mimickers of urothelial carcinoma and the clinical, immunohistochemical and molecular approaches that can prove useful for making the correct diagnosis. We highlight both the most common and the most difficult diagnostic dilemmas and pitfalls that we have seen in our clinical practice.</div></div>","PeriodicalId":49548,"journal":{"name":"Seminars in Diagnostic Pathology","volume":"43 2","pages":"Article 150993"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146133450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TABLE OF CONTENTS (p/u from previous issue w/updates) 目录表（p/u来自上一期，更新）

IF 3.5 3区医学

Seminars in Diagnostic Pathology Pub Date : 2026-03-01 Epub Date: 2026-03-12 DOI: 10.1053/S0740-2570(26)00028-6

引用次数: 0

Advances in artificial intelligence in prostate cancer pathology 人工智能在前列腺癌病理中的研究进展。

IF 3.5 3区医学

Seminars in Diagnostic Pathology Pub Date : 2026-03-01 Epub Date: 2026-03-04 DOI: 10.1016/j.semdp.2026.150995

Garrett J. Chan , Chien-Kuang C. Ding

{"title":"Advances in artificial intelligence in prostate cancer pathology","authors":"Garrett J. Chan , Chien-Kuang C. Ding","doi":"10.1016/j.semdp.2026.150995","DOIUrl":"10.1016/j.semdp.2026.150995","url":null,"abstract":"<div><div>Prostate cancer is one of the most common cancers in men, and accurate pathology evaluation is crucial for risk stratification and treatment planning. Traditional approaches, such as Gleason grading, are limited by interobserver variability and restricted access to expert consultation and molecular testing worldwide. Advances in digital pathology and artificial intelligence (AI) present opportunities to overcome these challenges. Whole slide imaging (WSI) forms the foundation for AI research, enabling remote review, large-scale data sharing, and the development of automated tools for tumor detection, Gleason grading, and molecular prediction. AI applications now extend beyond diagnostic support to prognostic and predictive modeling, including risk of recurrence and treatment response. Despite rapid progress, limitations persist, including data size, ground truth variability, training sets predominantly sourced from high-resource settings, and the “black-box” nature of AI outputs. Pathologists generally view AI as supportive tools, emphasizing the need for transparency, explainability, standardization, and trust. Overall, AI in digital pathology shows strong potential to augment pathology expertise, improve diagnostic efficiency and accuracy, and expand access to advanced cancer care globally. Continued collaboration between pathologists, clinicians, and researchers will be essential to ensure safe, equitable adoption.</div></div>","PeriodicalId":49548,"journal":{"name":"Seminars in Diagnostic Pathology","volume":"43 2","pages":"Article 150995"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147437010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

EDITORIAL BOARD (p/u from previous issue) 编辑委员会（p/u自上期）

IF 3.5 3区医学

Seminars in Diagnostic Pathology Pub Date : 2026-03-01 Epub Date: 2026-03-12 DOI: 10.1053/S0740-2570(26)00027-4

引用次数: 0

Molecular Advances in Gastrointestinal Pathology 胃肠病理学的分子进展

IF 3.5 3区医学

Seminars in Diagnostic Pathology Pub Date : 2026-03-01 Epub Date: 2026-01-24 DOI: 10.1016/j.semdp.2026.150990

Avash Das , Paolo M. Chetta , M. Lisa Zhang

{"title":"Molecular Advances in Gastrointestinal Pathology","authors":"Avash Das , Paolo M. Chetta , M. Lisa Zhang","doi":"10.1016/j.semdp.2026.150990","DOIUrl":"10.1016/j.semdp.2026.150990","url":null,"abstract":"<div><div>Gastrointestinal adenocarcinomas, including colorectal cancer (CRC) and gastroesophageal junction (GEJ) carcinoma, represent a significant global health burden. Recent advances in large-scale multi-omics profiling, particularly through The Cancer Genome Atlas (TCGA), have revealed the genetic heterogeneity and underlying biology of these tumors. Integrating molecular biomarkers with histopathology into routine practice guides classification, prognosis, and targeted interventions. In CRC, hypermutated subtypes—defined by microsatellite instability (MSI) or polymerase epsilon (POLE) mutations—demonstrate high tumor mutational burden (TMB) and robust response to immune checkpoint blockade. Alternatively, non-hypermutated tumors, driven by chromosomal instability, harbor recurrent alterations in <em>RAS, BRAF, HER2</em>, and <em>NTRK</em>, enabling biomarker-based stratification for targeted therapies. Exploratory markers such as <em>PIK3CA</em> mutations and TMB are being investigated, although their predictive value in microsatellite-stable CRC remains limited. Similarly, GEJ carcinomas can be classified into four molecular subgroups: Epstein–Barr virus (EBV)–associated, MSI, chromosomal instability, and genomically stable. Each subtype is defined by characteristic biology and carries distinct therapeutic implications, with actionable targets including HER2 amplification, PD-L1 expression, and claudin 18.2 (CLDN18.2). Established clinical biomarkers such as MSI, PD-L1, and HER2 are standard in precision oncology, while emerging markers like CLDN18.2, TMB, and <em>KRAS</em> G12C, extend the therapeutic landscape. Combining biomarker-driven immunotherapy and targeted approaches such as PD-1 blockade in MSI-H or EBV-positive tumors, HER2-directed therapy, and CLDN18.2 inhibition, has demonstrated a paradigm shift in the clinical management. This review highlights a pathologist-centered perspective on molecularly defined subgroups, actionable biomarkers, and evolving therapeutic paradigms in CRC and GEJ carcinoma, advancing precision oncology.</div></div>","PeriodicalId":49548,"journal":{"name":"Seminars in Diagnostic Pathology","volume":"43 2","pages":"Article 150990"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146098894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fusion-positive soft tissue tumors: A selective review 融合阳性软组织肿瘤：选择性回顾。

IF 3.5 3区医学

Seminars in Diagnostic Pathology Pub Date : 2026-03-01 Epub Date: 2026-03-04 DOI: 10.1016/j.semdp.2026.150997

Laura M. Warmke , Andrew L. Folpe

{"title":"Fusion-positive soft tissue tumors: A selective review","authors":"Laura M. Warmke , Andrew L. Folpe","doi":"10.1016/j.semdp.2026.150997","DOIUrl":"10.1016/j.semdp.2026.150997","url":null,"abstract":"<div><div>Even for experts, the diagnosis of soft tissue tumors remains challenging, owing to their rarity, striking diversity, and sometimes subtle morphological differences. Over the past decade, however, significant advances have been made in our collective understanding of the molecular genetic pathogenesis of these rare lesions, especially with the discovery that many are characterized by the presence of characteristic gene fusions, which can be exploited for diagnostic purposes. This review article focuses on four fusion-driven soft tissue tumors which illustrate different aspects of our evolving understanding of these tumors: (1) <em>NUTM1</em>-rearranged sarcoma, a prototypical example of a novel, clinically significant entity defined almost entirely by molecular genetics; (2) <em>SRF</em>-rearranged myoid neoplasm, an entity whose recognition greatly clarifies our understanding of pediatric “leiomyosarcomas;” (3) superficial FET-ETS neurocristic tumor, a very recently described, clinically benign entity sharing identical fusion events with often-lethal Ewing sarcoma; and (4) an evolving family of glomoid/myoid neoplasms harboring <em>EWSR1</em>::<em>WT1</em> fusions, but clearly differing from desmoplastic small round cell tumor. These examples illustrate the complexity of fusion-driven soft tissue tumors and the importance of integrating molecular genetic testing with other clinicopathological data, rather than viewing it in isolation.</div></div>","PeriodicalId":49548,"journal":{"name":"Seminars in Diagnostic Pathology","volume":"43 2","pages":"Article 150997"},"PeriodicalIF":3.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147436960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pleomorphic adenoma: A comprehensive review 多形性腺瘤：综述。

IF 3.5 3区医学

Seminars in Diagnostic Pathology Pub Date : 2026-03-01 Epub Date: 2026-01-29 DOI: 10.1016/j.semdp.2026.150991

Wilson Duplessis, Jason K. Wasserman

引用次数: 0